Synaptiq Therapeutics Launches with Acquisition of Clinical-Stage SYN-001 Program

Contributed by: PR Newswire

Tags

SynaptiqTher-ArcticTh

More Like This

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing

Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset

Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health

Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions

Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer's Disease

PR Newswire associated0

NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder

BioArctic receives Orphan Drug Designation for exidavnemab the US

PR Newswire associated0

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study